Authors' objectives: reatment of multiple myeloma (MM). Elotuzumab is a humanised recombinant monoclonal IgG1 antibody product directed to human CS1, a cell surface glycoprotein that is highly expressed on MM cells. MM is the 17th most common cancer in the UK, accounting for around 1% of all new cases. It is the second most common haematological cancer in the UK, affecting 1.5 times more men than women, and is twice as common in people of African or Caribbean descent compared with those from White ethnic groups. The crude incidence rate of myeloma was 9 per 100,000 population in England in men, and 7 per 100,000 population in women. In 2010-11, 33% of adult myeloma patients were predicted to survive ten or more years in England and Wales. In 2013-14, there were 105,265 admissions for MM in England, resulting in 85,572 bed days and 108,785 finished consultant episodes. During 2013, there were 2,403 deaths from MM registered in England and Wales. Myeloma is a clinically and genomically heterogeneous disease. Whilst responses to treatment and survival have improved significantly, it remains incurable and there are cohorts of patients whose management remains challenging. The main aims of therapy for MM are to prolong survival and maintain a good quality of life by controlling the disease and relieving symptoms. Treatment regimens are patient specific and dependent on performance status, eligibility for high dose chemotherapy with stem cell transplantation support, and frailty. Induction therapy followed by high-dose melphalan and autologous stem cell transplantation provides the greatest chance of prolonged survival and complete remission; however this typically only improves survival by up to a year. Currently, elotuzumab is in a phase III study in combination with lenalidomide and dexamethasone comparing its effect on progression-free survival vs lenalidomide and dexamethasone alone. This trial is expected to complete in February 2020.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/elotuzumab-with-lenalidomide-for-multiple-myeloma-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Centre (NIHR HSC)